Jim Simons Biovie Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.53 - $1.89 $184,122 - $656,586	347,400 New	347,400 $184,000
Q4 2022 Feb 13, 2023	BUY	$3.86 - $42.0 $1.06 Million - $11.5 Million	273,800 Added 1165.11%	297,300 $2.31 Million
Q3 2022 Nov 14, 2022	BUY	$1.38 - $25.6 $10,350 - $192,000	7,500 Added 46.88%	23,500 $59,000
Q2 2022 Aug 12, 2022	BUY	$1.44 - $5.04 $23,040 - $80,640	16,000 New	16,000 $23,000
Q4 2021 Feb 11, 2022	SELL	$4.41 - $6.99 $234,171 - $371,169	-53,100 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$6.69 - $16.93 $168,588 - $426,636	25,200 Added 90.32%	53,100 $355,000
Q2 2021 Aug 13, 2021	BUY	$10.57 - $21.61 $294,903 - $602,919	27,900 New	27,900 $473,000

4.73M

17.2K

27K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $83.6M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.